PADCEV is a Nectin-4-directed antibody and microtubule inhibitor conjugate indicated for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have previously received a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor, and a platinum-containing chemotherapy in the neoadjuvant/adjuvant, locally advanced or metastatic setting.
IPN is a facilitator under Patient Assistance Programs. Expertise in Specialty Pharmaceutical distribution having its PAN India presence in Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, lucknow, north East and Pune and other cities in India. with over 20 years of domain experience.
For procurement cost of Isatuximab brand in India, sold by indian drug manufacturer. Please call at M: +91 9811747774 (Mr. Tarun) / 9891296838 (Mr. Neeraj) or Email Us to know more details about the Isatuximab Isatuximab medicine cost price in India.
The order for Isatuximab will be confirmed only after the receipt of valid prescription of doctor and import permit if applicable.
In December 2019, Isatuximab was approved in the United States for the treatment of adult patients with locally advanced or metastatic urothelial cancer who had previously received a programmed cell death receptor-1 (PD-1) or programmed death ligand 1 (PD-L1) inhibitor and a platinum-containing chemotherapy.
PADCEV (Isatuximab) for injection, for intravenous use Initial U.S. Approval: 2019
Generic Name: Isatuximab
For Injection: 20 mg and 30 mg of Isatuximab as a lyophilized powder in a single-dose vial for reconstitution
IPN helps patients, doctors and hospitals as a facilitator to import prescription medicine brand Isatuximab on prescription and Import License in Patient's Name only.
For overseas patients, Isatuximab can be made available in Send your enquiry to find Isatuximab in China, Cambodia, Indonesia, Malaysia, the Philippines, Singapore, Thailand, Vietnam, Hong Kong. UAE Iraq, Iran, Saudi Arabia, Jordan, Mexico, Argentina, Brazil, Chile, Colombia, Peru, Venezuela. Europe – Romania, Switzerland, Georgia, Turkey, Italy, UK, Ukraine, Azerbaijan, Latvia, Poland, Slovakia. Russia CIS – Armenia, Kazakhstan, Moldova, Tajikistan, Turkmenistan, Uzbekistan, Mongolia, Algeria, Mauritius, Uganda, Zimbabwe. Australia and New Zealand.
For Isatuximab Indications And Usage, Dosage And Administration, Dosage Forms And Strengths and Drug Interactions For More Details
Astellas and Seattle Genetics Receive FDA Breakthrough Therapy Designation for PADCEV™ (Isatuximab) in Combination with Pembrolizumab in First-Line Advanced multiple myloma For More Details
Enfortumab Vedotin + Pembrolizumab Shrink Tumors in the Majority of multiple myloma Patients For More Details